Elevated zero maze: A paradigm to evaluate antianxiety effects of drugs

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 29, Issue 5, 2007, Pages 343-348

  Kulkarni, Shrinivas K ^a,b   Singh, K ^a   Bishnoi, M ^b  

^a PANJAB UNIVERSITY   (India)

^b PANJAB UNIVERSITY   (India)

Author keywords

Anxiety; Bidirectional; Plus maze; Zero maze

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ALCOHOL; ALPRAZOLAM; ANXIOLYTIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR; CHLORDIAZEPOXIDE; DIAZEPAM; FLUMAZENIL; LORAZEPAM; NITRAZEPAM; PENTETRAZOLE; PENTOBARBITAL; PHENOBARBITAL; PICROTOXIN; TRIAZOLAM; ZOLPIDEM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; FEMALE; LATENT PERIOD; MALE; MAZE TEST; MOUSE; NONHUMAN;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; FEMALE; MALE; MICE; MICE, INBRED STRAINS;

EID: 34548363505     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2007.29.5.1117557     Document Type: Article

References (13)

1. Kulkarni, S.K., Reddy, D.S. Animal behavioral models for testing antianxiety agents. Methods Find Exp Clin Pharmacol 1996, 18(3): 219-30.
2. Shepherd, J.K., Grewal, S.S. Behavioral and pharmacological characterisation of the elevated "zero maze" as an animal model of anxiety. Psychopharmacology 1994, 116: 56-64.
3. Shepherd, J.K., Grewal, S.S. Pharmacological evaluation of the elevated "zero maze" as model of anxiety in rats. Br J Pharmacol 1993, 110: 13P.
4. Shepherd, J.K. Preliminary evaluation of an elevated "zero maze" as a model of anxiety in laboratory rats. J Psychopharmacol 1992, 6(A56): 223.
5. Schwartz, T.L., Nihalni, N. History repeats itself: Pharmacodynamics trends in treatment of anxiety disorders. Curr Pharmaceutical Des 2005, 11: 255-63.
6. Roy-Byrne, P.P. The GABA-benzodiazepines receptor complex: Structure, function and role in anxiety. J Clin Psychiatry 2005, 66(Suppl 2): 14-20.
7. Bormann, J. The ABC of GABA receptors. Trends Pharmacol Sci 2000, 21: 16-19.
8. Lydiard, R.B. The role of GABA in anxiety disorders. J Clin Psychiatry 2003, 64(Suppl 3): 21-7.
9. Zohar, J., Westenberg, H.G. Anxiety disorders and selective serotonin reuptake inhibitors. Acta Psychiatr Scand 2000, 403: 39-49.
10. Kulkarni, S.K. Hand Book of Experimental Pharmacology, 3rd ed. Vallabh Prakashan: Delhi 1999.
11. Pellow, S., File, S.E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: A novel test of anxiety in the rat. Pharmacol Biochem Behav 1986, 24(3): 525-9.
12. Toubas, P.L., Abla, K.A., Cao, W., Logan, L.G., Seale, T.W. Latency to enter a mirrored chamber: A novel behavioral assay for anxiolytic agents. Pharmacol Biochem Behav 1986, 35(1): 121-6.
13. Lee, C., Rodgers, R.J. Effect of benzodiazepine antagonist on anti nociceptive and behavioral responses to elevated plus maze in mice. Neuropharmacology 1991, 30(12A): 1263-7.